Disc Medicine, Inc.

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
61.18 ^USD	+1.39%		-8.17%	-22.96%

Feb. 27	Disc Medicine's board approves restructuring plan	RE
Feb. 26	Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

Published on 02/17/2026 at 11:23 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Disc Medicine, Inc.

Feb. 27	Disc Medicine's board approves restructuring plan	RE
Feb. 26	Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 26	Disc Medicine's 2025 Net Loss Widens	MT
Feb. 19	Disc Medicine Insider Sold Shares Worth $719,727, According to a Recent SEC Filing	MT
Feb. 18	Disc Medicine Insider Sold Shares Worth $347,679, According to a Recent SEC Filing	MT
Feb. 18	Disc Medicine Insider Sold Shares Worth $833,775, According to a Recent SEC Filing	MT
Feb. 17	Disc Medicine Plans FDA Response on Bitopertin With Phase 3 Results; Shares Rise	MT
Feb. 17	Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says	MT
Feb. 17	Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating	MT
Feb. 17	Disc Medicine, Inc. - Special Call
Feb. 17	Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod	RE
Feb. 17	Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route	RE
Feb. 13	Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval	DJ
Feb. 13	Disc Medicine receives complete response letter from FDA for bitopertin for the treatment of EPP	RE
Feb. 13	Disc Medicine Drug Bitopertin Receives FDA Response	MT

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Employees

155

Sector

Biotechnology & Medical Research

More about the company